Olfaction in chemotherapy for head and neck malignancies

Haxel, Boris; Berg, Stephanie; Boessert, Patrick; Mann, Wolf J.; Fruth, Kai

doi:10.1016/j.anl.2015.07.004

Cited by 10 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All patients presented a normal olfactory function after completing therapy. These results were confirmed by other studies [8,11,12]. This is not surprising as olfactory sensory cells are unique among the sensory cells of humans because they are capable for renewing.…”

Section: Discussionsupporting

confidence: 88%

“…These findings are in accordance with Haxel et al, who enrolled 33 patients with malignancies in the head and neck region undergoing chemotherapy (cis-, carboplatin, 5-fluoruracil and docetaxel) for evaluation of the sense of smell. They could demonstrate a significant decrease in TDI score during the chemotherapy [8]. In addition, in a cohort of 87 cancer patients (breast cancer or gynecologic malignancies) undergoing various chemotherapy regimens (27% of those platinum containing) it could be demonstrated that olfactory function decreased significantly during chemotherapy but recovered almost completely after termination of the therapy [13].…”

Section: Discussionmentioning

confidence: 94%

“…As the subjective rating of olfactory function has been shown to be notoriously inaccurate, it is necessary to measure olfactory function [5]. There are some studies which measured olfactory function psychophysically during versus after chemotherapy with inconclusive findings though [2][3][4][5][6][7][8][9][10][11][12][13][14]. However, chemosensory alterations, especially olfactory and taste distortions have been reported in cancer patients in general.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Testicular cancer patients undergoing cisplatin based chemotherapy exhibit temporary olfactory threshold scores changes

Walliczek‐Dworschak

Gudziol

Mitzschke

et al. 2017

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Testicular cancer is the most frequent malignant disease in young males between 15 and 35 years. Platinum based chemotherapy regimen is the therapy of choice in advanced disease. This treatment has also adverse effects caused by the cytostatic active substances, such as olfactory dysfunctions. The aim of this study was, therefore, to monitor olfactory function of testicular cancer patients during and 6 months after chemotherapy. A total of 17 patients (mean age 31.06 ± 10.26 years), which underwent chemotherapy (mean 2.47 cycles ± 0.5) were enrolled in this study. Odor threshold, discrimination and identification were assessed by means of the "Sniffin' Sticks" prior to and on day 42, 90 and 180 after chemotherapy has been completed. Furthermore, patients' ratings of olfactory function and depressive symptoms were evaluated. Threshold scores were significantly lower on day 90 (8.0 ± 2.51) compared to baseline (10.4 ± 2.20) (p = 0.014) and recovered almost completely on day 180 (9.65 ± 3.26). Odor discrimination and identification did not show significant changes during therapy. The decrease of the olfactory function during/immediately after chemotherapy was underlined by the subjectively perceived impaired olfactory function during this time. In addition almost every fourth patient presented with a depressed mood at the beginning of chemotherapy. Patients should be informed about possible transient olfactory impairment during/immediately after chemotherapy.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Testicular cancer patients undergoing cisplatin based chemotherapy exhibit temporary olfactory threshold scores changes

Walliczek‐Dworschak

Gudziol

Mitzschke

et al. 2017

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

show abstract

“…However, the majority of cancer patients after chemotherapy do not exhibit parosmia, with only 30% consistently experiencing it, predominantly observed in elderly patients. This aligns with the findings of Haxel et al (2016) [ 24 ], who conducted a study on 28 patients using the Sniffin' Sticks test. The mechanism behind the pathogenesis of parosmia after chemotherapy is explained in the chart below(Figure 7 ) [ 25 ].…”

Section: Discussionsupporting

confidence: 91%

A Subjective Assessment of Chemotherapy Drug-Induced Taste and Smell Alteration in Non-head and Neck Cancer Patients: A Questionnaire-Based Cross-Sectional Study

Yadav,

Mittal,

Reddy

et al. 2024

Cureus

View full text Add to dashboard Cite

Objective: This study aimed to evaluate alterations in taste and smell perceptions among non-head and neck cancer patients receiving chemotherapy, aiming to identify factors influencing these changes. Methods: A cohort of 70 non-head and neck cancer patients undergoing one to four cycles or more than four cycles, over a six-month period, from oncology outpatient clinics was recruited. Participants completed structured taste and smell questionnaires with assistance from interviewers. Demographic data, recurrence history, chemotherapy cycles, drug regimens, and taste and smell perceptions were analyzed using descriptive statistics and chi-square tests. Results: The mean age of participants was 46.5 years, with a predominance of females (81.4%) and breast cancer cases (42.9%). Taste changes were more prevalent (62.9%) than smell changes (32.9%) post chemotherapy, particularly among those on combination drug regimens. Salty taste alterations were the most common (30.0%), followed by sweet taste (22.9%) and sour/bitter tastes (14.3%). Moreover, 38.57% of patients reported experiencing dysgeusia, while 30% noted the occurrence of parosmia post chemotherapy. Conclusion: Chemotherapy-induced alterations in taste and smell significantly impact the quality of life and nutritional status of cancer patients. Despite often being overlooked, these changes warrant increased attention in oncological practice to inform treatment decisions and enhance symptom management, particularly in palliative care settings. Further research is needed to explore the implications of chemosensory alterations on patient outcomes and treatment strategies.

show abstract

“…6,7 Both radioand chemotherapy are also associated with dysgeusia (altered taste) and dysosmia (altered smell). 3,8,9 While these may not directly cause dysphagia, chemosensory input modulates swallow responsiveness, with increased sensory input providing better swallow response. 10 Targeted (or biological) therapies refer to drugs that interfere with carcinogenesis and tumor growth.…”

Section: Introductionmentioning

confidence: 99%

Dysphagia in Solid Tumors Outside the Head, Neck or Upper GI Tract: Clinical Characteristics

Kenny

Regan

Balding³

et al. 2022

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

Olfaction in chemotherapy for head and neck malignancies

Cited by 10 publications

References 23 publications

Testicular cancer patients undergoing cisplatin based chemotherapy exhibit temporary olfactory threshold scores changes

Testicular cancer patients undergoing cisplatin based chemotherapy exhibit temporary olfactory threshold scores changes

A Subjective Assessment of Chemotherapy Drug-Induced Taste and Smell Alteration in Non-head and Neck Cancer Patients: A Questionnaire-Based Cross-Sectional Study

Dysphagia in Solid Tumors Outside the Head, Neck or Upper GI Tract: Clinical Characteristics

Contact Info

Product

Resources

About